CAR T-cell Therapy in Lymphoma

Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.

CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

Non-Hodgkin Lymphoma

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Keynote Conference

Mednews Week

Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma. 

Strategies to Improve CAR T-cell Durability in Lymphoma